MacroGenics, Inc.

MacroGenics, Inc. reported a net loss of $74.6 million for fiscal year 2025, driven by an operating loss of $72.8 million. Total revenues were $149.5 million, while total costs and expenses amounted to $222.3 million, with research and development costs of $147.2 million representing the largest expense category. The company's cash position declined by $125.6 million during the year, ending with $108.9 million in cash and cash equivalents, supported by $69.5 million in net cash from financing activities primarily from the sale of future royalties. The balance sheet shows total assets of $256.8 million against total liabilities of $201.3 million, resulting in stockholders' equity of $55.6 million. The company continues to operate at a loss while maintaining significant investment in research and development activities.

Key Takeaways